Skip to content
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Rheumatology · Connective Tissue Disease-Associated Interstitial Lung Disease

Can Autoimmune Diseases Cause Lung Scarring or ILD?

At a Glance

Rheumatoid arthritis and several other autoimmune diseases can affect the lungs, causing inflammation or interstitial lung scarring. Early disease may have no symptoms, so pulmonary function tests and high-resolution CT scans help guide monitoring and treatment.

Yes, rheumatoid arthritis and other autoimmune diseases can cause lung problems, including lung scarring. In autoimmune conditions, your immune system mistakenly attacks your body’s own healthy tissues. Just as it can attack your joints or skin, it can also affect your lungs [1]. When this immune system attack leads to inflammation or scarring in the lungs, doctors refer to it as Connective Tissue Disease-Associated Interstitial Lung Disease (CTD-ILD).

Learning that your rheumatoid arthritis (RA) or autoimmune disease could affect your lungs can be frightening. However, having an autoimmune condition does not guarantee you will develop severe lung disease, and early assessment can help guide your care.

How Do Autoimmune Diseases Affect the Lungs?

The term interstitial refers to the supporting tissue and space around the delicate air sacs in your lungs. When your immune system targets this area, it triggers persistent inflammation [2].

This condition can involve two main processes:

  • Inflammation: Active swelling and immune cell activity in the lungs. With proper treatment, this inflammation can sometimes improve.
  • Fibrosis (Scarring): If chronic inflammation injures the air sacs, your body may produce excess collagen to repair it, leading to thick, stiff scar tissue [3]. This scarring is permanent and makes it harder for your lungs to expand and transfer oxygen into your bloodstream.

It is important to know that CTD-ILD is not just another word for permanent scarring; the disease can be mainly inflammatory, mainly fibrotic, or a mix of both. Your lung condition could remain stable, improve with treatment, or progress, depending on your specific disease and other individual factors [4].

Which Autoimmune Conditions Are Linked to ILD?

Several autoimmune diseases can cause CTD-ILD, but they interact with the lungs differently:

  • Rheumatoid Arthritis (RA): It is common for RA to affect the lungs, sometimes even before joint symptoms appear [5]. While between 20% and 60% of people with RA may have subtle lung abnormalities on a scan, not all of these become clinically significant or progress to severe scarring [6]. When significant scarring does occur, it often follows a pattern called Usual Interstitial Pneumonia (UIP) [6]. Factors that increase your risk include smoking, older age, poorly controlled joint disease, and having high levels of certain RA antibodies [7].
  • Scleroderma (Systemic Sclerosis): This condition frequently involves the lungs [1]. Interstitial lung disease affects roughly 47% of people with scleroderma and is driven by a mix of immune system activity and blood vessel damage [8][9]. The most common pattern of lung involvement in scleroderma is Nonspecific Interstitial Pneumonia (NSIP) [10].
  • Lupus (Systemic Lupus Erythematosus): Lupus tends to cause active inflammation—such as pleuritis (inflammation of the lining around the lungs), pleural effusion (fluid around the lungs), or pneumonitis (inflamed lung tissue)—rather than severe chronic scarring [11]. Only a small percentage of people with lupus develop fibrotic lung disease compared to those with scleroderma [9].
  • Other Conditions: Sjögren’s disease, mixed connective-tissue disease, and inflammatory muscle diseases (myositis) can also cause CTD-ILD [1].

Note: Autoimmune diseases can also cause other lung issues besides ILD, such as airway disease, medication-related lung injury, or pulmonary hypertension.

What Symptoms Should I Watch For?

Early on, you might not have any symptoms. As the condition develops, you may notice:

  • Shortness of breath, especially during exercise or exertion
  • A persistent, dry cough
  • Unexplained fatigue or a reduced ability to exercise

When to seek immediate care: Contact a doctor urgently if you experience sudden or rapidly worsening breathlessness, severe chest pain, coughing up blood, blue lips, or fainting.

How is CTD-ILD Evaluated and Monitored?

If your doctor suspects lung involvement, or to monitor an existing diagnosis, they may use several tests:

  • Pulmonary Function Tests (PFTs): Breathing tests that measure how much air your lungs can hold and how well they transfer oxygen (a measurement called DLCO) [12].
  • High-Resolution CT (HRCT) Scan: A detailed chest X-ray that creates cross-sectional images of your lungs to look for inflammation or scarring [13].

Your care team will determine your testing schedule based on your symptoms, risk factors, and whether your condition is stable or changing.

How is CTD-ILD Treated?

Treatment is highly individualized. It depends on your specific autoimmune disease, the pattern of lung involvement on your CT scan, the severity of your symptoms, and whether your lung function is declining. Never start, stop, or change your RA or autoimmune medications without speaking to your doctor, as this requires careful coordination.

  • Observation: If your ILD is mild, stable, and not causing symptoms, your doctor might recommend regular monitoring without adding new lung medications.
  • Immunosuppressants: If active inflammation is driving your lung disease, your doctor might prescribe medications that quiet the immune system, such as mycophenolate or rituximab [14]. These may help stabilize your lung function, but they require careful monitoring for side effects, including an increased risk of infection [15].
  • Antifibrotic Medications: If your lung scarring continues to worsen (a condition called progressive pulmonary fibrosis), your doctor might prescribe an antifibrotic drug like nintedanib [16]. These medications do not reverse existing scars, but they can help slow down the decline in lung function [17]. They can be used alone or sometimes in combination with immunosuppressants, and require monitoring for side effects like diarrhea or liver issues [18].
  • Supportive Care and Lifestyle:
    • Smoking Cessation: Quitting smoking and avoiding inhaled dust or fumes are critical steps to protect your lungs [7].
    • Pulmonary Rehabilitation: Structured exercise and education programs that help improve your breathing and exercise tolerance [19].
    • Vaccinations: Staying up-to-date on vaccines (like influenza and pneumonia) helps prevent respiratory infections [20].
    • Supplemental Oxygen: If testing shows your blood oxygen levels are low, your doctor may prescribe oxygen therapy [21].
    • Managing Acid Reflux: If you experience acid reflux, treating it can help prevent stomach acid from reaching your lungs and worsening your condition [21].

Because everyone’s condition is different, your care should ideally involve a collaborative, multidisciplinary team, including a rheumatologist (to manage the autoimmune disease) and a pulmonologist (to manage the lung disease) [17].

Common questions in this guide

Can rheumatoid arthritis cause interstitial lung disease or lung scarring?
Yes. Rheumatoid arthritis can cause inflammation or scarring in the lungs, but not everyone with rheumatoid arthritis develops severe or progressive lung disease. The lung problem may be mainly inflammatory, mainly scar-related, or a mixture of both.
Which autoimmune diseases can affect the lungs?
Rheumatoid arthritis, systemic sclerosis or scleroderma, lupus, Sjögren disease, mixed connective-tissue disease, and inflammatory muscle diseases can all affect the lungs. The type and severity of lung involvement can differ between conditions.
What symptoms could mean my autoimmune disease is affecting my lungs?
Early lung involvement may cause no symptoms. Possible signs include shortness of breath with activity, a persistent dry cough, fatigue, or reduced exercise ability. Sudden worsening breathlessness, severe chest pain, coughing up blood, blue lips, or fainting requires urgent medical attention.
What tests are used to check for autoimmune-related interstitial lung disease?
Pulmonary function tests measure breathing capacity and how well the lungs transfer oxygen, including a measurement called DLCO. A high-resolution CT scan provides detailed images that can show inflammation or scarring. Your care team decides how often to repeat testing based on your symptoms, risk factors, and disease stability.
How is lung disease caused by an autoimmune condition treated?
Treatment depends on the autoimmune disease, the pattern and severity of lung involvement, symptoms, and whether lung function is declining. Options may include monitoring, immune-suppressing medicines, an antifibrotic medicine such as nintedanib for progressive scarring, pulmonary rehabilitation, oxygen, vaccinations, and treatment for acid reflux.
Could my autoimmune medicines affect my lungs or help protect them?
Some medicines may help control the immune inflammation affecting the lungs, while medication-related lung injury is also possible with some treatments. Do not start, stop, or change an autoimmune medicine on your own; your rheumatologist and pulmonologist should coordinate the decision.
When should I seek urgent care for possible autoimmune-related lung disease?
Seek urgent medical care for sudden or rapidly worsening shortness of breath, severe chest pain, coughing up blood, blue lips, or fainting. These symptoms can signal a serious breathing or circulation problem and should not wait for a routine appointment.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given my autoimmune diagnosis, how often should my lung function be tested with pulmonary function tests or a CT scan?
  2. 2.Could any of the medications I currently take for my joint symptoms also help protect my lungs, or do I need a different treatment?
  3. 3.What specific respiratory symptoms should I watch for that might indicate my autoimmune disease is affecting my lungs?
  4. 4.Does my specific antibody profile or disease activity put me at a higher risk for developing progressive lung complications?
  5. 5.If I need treatment for lung scarring, how will my rheumatologist and pulmonologist coordinate my care to avoid medication conflicts?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Connective tissue disease-associated interstitial lung disease: an approach to treatment amidst an expanding evidence base.

    Hong M, Veitch E, Limaye S

    Internal medicine journal 2025; (55(6)):885-894 doi:10.1111/imj.70026.

    PMID: 40051385
  2. 2

    Pathogenesis of systemic sclerosis associated interstitial lung disease.

    Nihtyanova SI, Denton CP

    Journal of scleroderma and related disorders 2020; (5(2 Suppl)):6-16 doi:10.1177/2397198320903867.

    PMID: 35382227
  3. 3

    Citrullinated and malondialdehyde-acetaldehyde-modified fibrinogen activates macrophages and promotes profibrotic responses in human lung fibroblasts.

    Aripova N, Duryee MJ, Zhou W, et al.

    American journal of physiology. Lung cellular and molecular physiology 2025; (328(1)):L134-L147 doi:10.1152/ajplung.00153.2024.

    PMID: 39560968
  4. 4

    Relationship between idiopathic interstitial pneumonias (IIPs) and connective tissue disease-related interstitial lung disease (CTD-ILD): A narrative review.

    Enomoto N

    Respiratory investigation 2024; (62(3)):465-480 doi:10.1016/j.resinv.2024.03.006.

    PMID: 38564878
  5. 5

    Interstitial lung disease throughout the rheumatoid arthritis disease course.

    McDermott GC, Doyle TJ, Sparks JA

    Current opinion in rheumatology 2021; (33(3)):284-291 doi:10.1097/BOR.0000000000000787.

    PMID: 33625044
  6. 6

    The role of lung ultrasound B-lines and serum KL-6 in the screening and follow-up of rheumatoid arthritis patients for an identification of interstitial lung disease: review of the literature, proposal for a preliminary algorithm, and clinical application to cases.

    Wang Y, Chen S, Zheng S, et al.

    Arthritis research & therapy 2021; (23(1)):212 doi:10.1186/s13075-021-02586-9.

    PMID: 34391465
  7. 7

    Risk factors for interstitial lung disease in early rheumatoid arthritis and external validation of screening strategies: a cross-sectional analysis of the prospective SAIL-RA cohort in the USA.

    McDermott GC, Gill R, Byrne S, et al.

    The Lancet. Rheumatology 2025; (7(12)):e851-e863 doi:10.1016/S2665-9913(25)00158-4.

    PMID: 41106411
  8. 8

    Prevalence and evolution of scleroderma pattern at nailfold videocapillaroscopy in systemic sclerosis patients: Clinical and prognostic implications.

    Ghizzoni C, Sebastiani M, Manfredi A, et al.

    Microvascular research 2015; (99()):92-5.

    PMID: 25842153
  9. 9

    Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease: a systematic review and meta-analysis.

    Joy GM, Arbiv OA, Wong CK, et al.

    European respiratory review : an official journal of the European Respiratory Society 2023; (32(167)) doi:10.1183/16000617.0210-2022.

    PMID: 36889782
  10. 10

    Interstitial lung disease pathology in systemic sclerosis.

    Konopka KE, Myers JL

    Therapeutic advances in musculoskeletal disease 2021; (13()):1759720X211032437 doi:10.1177/1759720X211032437.

    PMID: 34349846
  11. 11

    Pulmonary Complications of Systemic Lupus Erythematosus.

    Hannah JR, D'Cruz DP

    Seminars in respiratory and critical care medicine 2019; (40(2)):227-234 doi:10.1055/s-0039-1685537.

    PMID: 31137062
  12. 12

    Demographic and clinical predictors of progression and mortality in connective tissue disease-associated interstitial lung disease: a retrospective cohort study.

    Chan C, Ryerson CJ, Dunne JV, Wilcox PG

    BMC pulmonary medicine 2019; (19(1)):192 doi:10.1186/s12890-019-0943-2.

    PMID: 31672127
  13. 13

    [Latest news on RA-ILD].

    Schreiber T, Hagmeyer L, Kofler DM, et al.

    Pneumologie (Stuttgart, Germany) 2022; (76(9)):614-621 doi:10.1055/a-1895-9360.

    PMID: 36104017
  14. 14

    Learnings from clinical trials in patients with connective tissue disease-associated interstitial lung disease.

    Higuero Sevilla JP, Memon A, Hinchcliff M

    Arthritis research & therapy 2023; (25(1)):118 doi:10.1186/s13075-023-03090-y.

    PMID: 37422652
  15. 15

    Azathioprine for Connective Tissue Disease-Associated Interstitial Lung Disease.

    Boerner EB, Cuyas M, Theegarten D, et al.

    Respiration; international review of thoracic diseases 2020; (99(8)):628-636 doi:10.1159/000508540.

    PMID: 32663826
  16. 16

    Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications.

    Erre GL, Sebastiani M, Manfredi A, et al.

    Drugs in context 2021; (10()) doi:10.7573/dic.2020-8-6.

    PMID: 33505482
  17. 17

    ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease.

    Antoniou KM, Distler O, Gheorghiu AM, et al.

    The European respiratory journal 2026; (67(1)) doi:10.1183/13993003.02533-2024.

    PMID: 40907995
  18. 18

    Differences in Tolerability of Antifibrotic Agents Between Connective Tissue Disease-Associated and Non-connective Tissue Disease-Associated Interstitial Lung Disease.

    Nakamura T, Jinta T, Kitamura A, et al.

    Cureus 2025; (17(2)):e78750 doi:10.7759/cureus.78750.

    PMID: 40070627
  19. 19

    Current and emerging treatment options for interstitial lung disease in patients with rheumatic disease.

    Lee JS, Fischer A

    Expert review of clinical immunology 2016; (12(5)):509-20 doi:10.1586/1744666X.2016.1139454.

    PMID: 26752397
  20. 20

    Exacerbation of connective tissue disease-associated interstitial lung disease due to influenza vaccination.

    Okusaki T, Fukuhara K

    Respiratory medicine case reports 2021; (33()):101463 doi:10.1016/j.rmcr.2021.101463.

    PMID: 34401299
  21. 21

    Management of interstitial lung disease associated with connective tissue disease.

    Mathai SC, Danoff SK

    BMJ (Clinical research ed.) 2016; (352()):h6819 doi:10.1136/bmj.h6819.

    PMID: 26912511

This page is for informational purposes only and does not constitute medical advice. A rheumatologist or pulmonologist should interpret your symptoms and tests and guide treatment for possible CTD-ILD.

Get notified when new evidence is published on Interstitial lung disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.